CAMBRIDGE, MA, VistaPath, a provider of artificial intelligence (AI)-based, data-driven pathology processing platforms, has secured $4 million in seed funding.
VistaPath, a provider of artificial intelligence (AI)-based, data-driven pathology processing platforms, has secured $4 million in seed funding led by Moxxie Ventures with participation from NextGen Venture Partners and First Star Ventures.
VistaPath is modernizing pathology labs using computer vision and artificial intelligence. They provide clients with significant quality, workflow, and strategic benefits with the overall goal of delivering improved results for pathologists, clinicians, and patients. The Sentinel is the company's first product.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
